The supplier to the lab-in-the-loop strand. Adaptyv does not design proteins; it runs the automated lab that tells a model whether its designs bind. Throughput grew more than fivefold in a year to over 100 customers, and in August 2026 the company published a run in which Claude-designed binders against 16 targets were tested there, with 354 of 1,320 designs binding. The $40M Series A, led by Highland Europe, funds a tripling of lab capacity and a London lab.